Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Tandem Diabetes downgraded to Underweight from Overweight at Wells Fargo » 05:15
08/09/22
08/09
05:15
08/09/22
05:15
TNDM

TNDM

/

+

, PODD

Insulet

$263.07 /

-4.155 (-1.55%)

, MDT

Medtronic

$93.59 /

+0.3 (+0.32%)

Wells Fargo analyst Larry…

Wells Fargo analyst Larry Biegelsen double downgraded Tandem Diabetes (TNDM) to Underweight from Overweight with a price target of $49, down from $82. The analyst believes consensus estimates are too high as he sees downside risk to numbers from new competition in all four of Tandem's key growth lines. The Omnipod 5 from Insulet (PODD) will pressure new patent starts and renewals for Tandem, while Medtronic's (MDT) 780G will make it tough for Tandem to win conversions from Medtronic given the better than expected feedback on the new product so far, Biegelsen tells investors in a research note.

ShowHide Related Items >><<
TNDM TNDM
/

+

PODD Insulet
$263.07 /

-4.155 (-1.55%)

MDT Medtronic
$93.59 /

+0.3 (+0.32%)

TNDM TNDM
/

+

08/04/22 Craig-Hallum
Tandem Diabetes price target lowered to $105 from $156 at Craig-Hallum
08/04/22 Lake Street
Tandem Diabetes price target lowered to $150 from $200 at Lake Street
08/04/22 Cowen
Tandem Diabetes price target lowered to $107 from $141 at Cowen
08/04/22 Raymond James
Tandem Diabetes price target lowered to $92 from $125 at Raymond James
PODD Insulet
$263.07 /

-4.155 (-1.55%)

08/05/22 Canaccord
Insulet price target raised to $290 from $250 at Canaccord
08/05/22 Baird
Insulet price target raised to $300 from $245 at Baird
08/05/22 Raymond James
Insulet price target raised to $280 from $262 at Raymond James
08/05/22 Piper Sandler
Insulet price target raised to $235 from $230 at Piper Sandler
MDT Medtronic
$93.59 /

+0.3 (+0.32%)

07/20/22 Truist
Medtronic price target lowered to $97 from $111 at Truist
07/18/22 Stifel
Medtronic price target lowered to $105 from $125 at Stifel
07/06/22 Wolfe Research
Wolfe starts 'potential value trap' Medtronic at Underperform
07/06/22 Wolfe Research
Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform
TNDM TNDM
/

+

PODD Insulet
$263.07 /

-4.155 (-1.55%)

MDT Medtronic
$93.59 /

+0.3 (+0.32%)

PODD Insulet
$263.07 /

-4.155 (-1.55%)

TNDM TNDM
/

+

PODD Insulet
$263.07 /

-4.155 (-1.55%)

MDT Medtronic
$93.59 /

+0.3 (+0.32%)

MDT Medtronic
$93.59 /

+0.3 (+0.32%)

Over a week ago
Recommendations
Medtronic price target lowered to $97 from $111 at Truist » 09:30
07/20/22
07/20
09:30
07/20/22
09:30
MDT

Medtronic

$90.37 /

+2.38 (+2.70%)

Truist analyst Richard…

Truist analyst Richard Newitter lowered the firm's price target on Medtronic to $97 from $111 and keeps a Hold rating on the shares as part of a broader research note on MedTech names previewing Q2 earnings. The analyst says he sees "in-linish" organic revenue growth for the group, while steepening FX related and supply chain/inflationary pressures could pressure bias to EPS estimates for 2022-2023. For the company, Newitter also states Medtronic has idiosyncratic headwinds to contend with that will likely continue to limit organic upside opportunities.

ShowHide Related Items >><<
MDT Medtronic
$90.37 /

+2.38 (+2.70%)

MDT Medtronic
$90.37 /

+2.38 (+2.70%)

07/18/22 Stifel
Medtronic price target lowered to $105 from $125 at Stifel
07/06/22 Wolfe Research
Wolfe starts 'potential value trap' Medtronic at Underperform
07/06/22 Wolfe Research
Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform
07/05/22 Wolfe Research
Medtronic initiated with an Underperform at Wolfe Research
MDT Medtronic
$90.37 /

+2.38 (+2.70%)

MDT Medtronic
$90.37 /

+2.38 (+2.70%)

MDT Medtronic
$90.37 /

+2.38 (+2.70%)

MDT Medtronic
$90.37 /

+2.38 (+2.70%)

Recommendations
Medtronic price target lowered to $105 from $125 at Stifel » 07:37
07/18/22
07/18
07:37
07/18/22
07:37
MDT

Medtronic

$89.12 /

+1.615 (+1.85%)

Stifel analyst Rick Wise…

Stifel analyst Rick Wise lowered the firm's price target on Medtronic to $105 from $125 and keeps a Buy rating on the shares. Many of his targets had been based on multiples assigned well-before multiple economic and geopolitical headwinds pushed both market- and industry-wide share prices lower and he is adjusting his MedTech trading multiples ahead of Q2 earnings season, though Wise notes that his target changes "do not represent any fundamental shift in our positive long-term thinking for the MedTech industry or the potential for broad-based growth reacceleration."

ShowHide Related Items >><<
MDT Medtronic
$89.12 /

+1.615 (+1.85%)

MDT Medtronic
$89.12 /

+1.615 (+1.85%)

07/06/22 Wolfe Research
Wolfe starts 'potential value trap' Medtronic at Underperform
07/06/22 Wolfe Research
Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform
07/05/22 Wolfe Research
Medtronic initiated with an Underperform at Wolfe Research
06/01/22 Atlantic Equities
Medtronic downgraded to Neutral from Overweight at Atlantic Equities
MDT Medtronic
$89.12 /

+1.615 (+1.85%)

MDT Medtronic
$89.12 /

+1.615 (+1.85%)

MDT Medtronic
$89.12 /

+1.615 (+1.85%)

MDT Medtronic
$89.12 /

+1.615 (+1.85%)

Hot Stocks
Medtronic expands Health Equity Assitance Program for colon cancer screening » 10:02
07/15/22
07/15
10:02
07/15/22
10:02
MDT

Medtronic

$88.63 /

+1.125 (+1.29%)

Medtronic and the…

Medtronic and the American Society for Gastrointestinal Endoscopy announced they are expanding the Medtronic Health Equity Assistance Program for colon cancer screening in medically underserved communities across the United States, with support from Amazon Web Services's Health Equity Initiative. The GI Genius units provided as part of the program have increased from 50 to 133 systems being placed at 62 facilities.

ShowHide Related Items >><<
MDT Medtronic
$88.63 /

+1.125 (+1.29%)

MDT Medtronic
$88.63 /

+1.125 (+1.29%)

07/06/22 Wolfe Research
Wolfe starts 'potential value trap' Medtronic at Underperform
07/06/22 Wolfe Research
Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform
07/05/22 Wolfe Research
Medtronic initiated with an Underperform at Wolfe Research
06/01/22 Atlantic Equities
Medtronic downgraded to Neutral from Overweight at Atlantic Equities
MDT Medtronic
$88.63 /

+1.125 (+1.29%)

MDT Medtronic
$88.63 /

+1.125 (+1.29%)

MDT Medtronic
$88.63 /

+1.125 (+1.29%)

MDT Medtronic
$88.63 /

+1.125 (+1.29%)

Conference/Events
Medtronic to hold a conference call » 09:15
07/15/22
07/15
09:15
07/15/22
09:15
MDT

Medtronic

$87.50 /

-0.43 (-0.49%)

VP Weispfenning and…

VP Weispfenning and President of Patient Monitoring Chan discuss Medtronic's patient monitoring business on a conference call to be held on July 15 at 9:30 am.

ShowHide Related Items >><<
MDT Medtronic
$87.50 /

-0.43 (-0.49%)

MDT Medtronic
$87.50 /

-0.43 (-0.49%)

07/06/22 Wolfe Research
Wolfe starts 'potential value trap' Medtronic at Underperform
07/06/22 Wolfe Research
Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform
07/05/22 Wolfe Research
Medtronic initiated with an Underperform at Wolfe Research
06/01/22 Atlantic Equities
Medtronic downgraded to Neutral from Overweight at Atlantic Equities
MDT Medtronic
$87.50 /

-0.43 (-0.49%)

MDT Medtronic
$87.50 /

-0.43 (-0.49%)

MDT Medtronic
$87.50 /

-0.43 (-0.49%)

MDT Medtronic
$87.50 /

-0.43 (-0.49%)

Conference/Events
Medtronic to hold a conference call » 04:55
07/15/22
07/15
04:55
07/15/22
04:55
MDT

Medtronic

$87.50 /

-0.43 (-0.49%)

VP Weispfenning and…

VP Weispfenning and President of Patient Monitoring Chan discuss Medtronic's patient monitoring business on a conference call to be held on July 15 at 9:30 am.

ShowHide Related Items >><<
MDT Medtronic
$87.50 /

-0.43 (-0.49%)

MDT Medtronic
$87.50 /

-0.43 (-0.49%)

07/06/22 Wolfe Research
Wolfe starts 'potential value trap' Medtronic at Underperform
07/06/22 Wolfe Research
Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform
07/05/22 Wolfe Research
Medtronic initiated with an Underperform at Wolfe Research
06/01/22 Atlantic Equities
Medtronic downgraded to Neutral from Overweight at Atlantic Equities
MDT Medtronic
$87.50 /

-0.43 (-0.49%)

MDT Medtronic
$87.50 /

-0.43 (-0.49%)

MDT Medtronic
$87.50 /

-0.43 (-0.49%)

MDT Medtronic
$87.50 /

-0.43 (-0.49%)

Over a month ago
Conference/Events
Medtronic to hold a conference call » 17:05
07/14/22
07/14
17:05
07/14/22
17:05
MDT

Medtronic

$87.50 /

-0.43 (-0.49%)

VP Weispfenning and…

VP Weispfenning and President of Patient Monitoring Chan discuss Medtronic's patient monitoring business on a conference call to be held on July 15 at 9:30 am.

ShowHide Related Items >><<
MDT Medtronic
$87.50 /

-0.43 (-0.49%)

MDT Medtronic
$87.50 /

-0.43 (-0.49%)

07/06/22 Wolfe Research
Wolfe starts 'potential value trap' Medtronic at Underperform
07/06/22 Wolfe Research
Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform
07/05/22 Wolfe Research
Medtronic initiated with an Underperform at Wolfe Research
06/01/22 Atlantic Equities
Medtronic downgraded to Neutral from Overweight at Atlantic Equities
MDT Medtronic
$87.50 /

-0.43 (-0.49%)

MDT Medtronic
$87.50 /

-0.43 (-0.49%)

MDT Medtronic
$87.50 /

-0.43 (-0.49%)

MDT Medtronic
$87.50 /

-0.43 (-0.49%)

Hot Stocks
Medtronic receives FDA clearance for UNiD Spine Analyzer » 08:02
07/14/22
07/14
08:02
07/14/22
08:02
MDT

Medtronic

$87.90 /

-0.76 (-0.86%)

Medtronic has received…

Medtronic has received FDA 510(k) clearance for its UNiD Spine Analyzer v4.0 planning platform, which includes a new Degen Algorithm for degenerative spine procedures. The algorithm leverages machine learning to help surgeons plan and personalize procedures for patients undergoing lower lumbar spine surgery and predicts spinal compensation mechanisms six months after the operation. The UNiD ASI Degen Algorithm aims to help surgeons achieve spinal alignment by more accurately planning procedures and predicting spinal alignment after six months.

ShowHide Related Items >><<
MDT Medtronic
$87.90 /

-0.76 (-0.86%)

MDT Medtronic
$87.90 /

-0.76 (-0.86%)

07/06/22 Wolfe Research
Wolfe starts 'potential value trap' Medtronic at Underperform
07/06/22 Wolfe Research
Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform
07/05/22 Wolfe Research
Medtronic initiated with an Underperform at Wolfe Research
06/01/22 Atlantic Equities
Medtronic downgraded to Neutral from Overweight at Atlantic Equities
MDT Medtronic
$87.90 /

-0.76 (-0.86%)

MDT Medtronic
$87.90 /

-0.76 (-0.86%)

MDT Medtronic
$87.90 /

-0.76 (-0.86%)

MDT Medtronic
$87.90 /

-0.76 (-0.86%)

Options
Medtronic put volume heavy and directionally bearish » 15:15
07/12/22
07/12
15:15
07/12/22
15:15
MDT

Medtronic

$88.97 /

+0.02 (+0.02%)

Bearish flow noted in…

Bearish flow noted in Medtronic with 4,167 puts trading, or 1.2x expected. Most active are 7/22 weekly 91 puts and 7/22 weekly 83 puts, with total volume in those strikes near 3,400 contracts. The Put/Call Ratio is 3.57, while ATM IV is up over 1 point on the day. Earnings are expected on August 23rd.

ShowHide Related Items >><<
MDT Medtronic
$88.97 /

+0.02 (+0.02%)

MDT Medtronic
$88.97 /

+0.02 (+0.02%)

07/06/22 Wolfe Research
Wolfe starts 'potential value trap' Medtronic at Underperform
07/06/22 Wolfe Research
Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform
07/05/22 Wolfe Research
Medtronic initiated with an Underperform at Wolfe Research
06/01/22 Atlantic Equities
Medtronic downgraded to Neutral from Overweight at Atlantic Equities
MDT Medtronic
$88.97 /

+0.02 (+0.02%)

MDT Medtronic
$88.97 /

+0.02 (+0.02%)

MDT Medtronic
$88.97 /

+0.02 (+0.02%)

MDT Medtronic
$88.97 /

+0.02 (+0.02%)

Hot Stocks
Medtronic enters strategic partnership agreement with CathWorks » 09:03
07/12/22
07/12
09:03
07/12/22
09:03
MDT

Medtronic

$88.94 /

-0.54 (-0.60%)

Medtronic announced it…

Medtronic announced it has entered into a strategic partnership agreement with CathWorks, a privately held company headquartered in Kefar Sava, Israel, which aims to transform how coronary artery disease is diagnosed and treated. As part of the agreement, Medtronic will invest up to $75M and immediately begin co-promotion of CathWorks' FFRangio System in the U.S., Europe and Japan, where it is commercially available. As part of a separate agreement, Medtronic will have the option to acquire CathWorks once certain undisclosed milestones are met. CathWorks will also have the right to compel Medtronic to acquire the company if Medtronic chooses not to exercise its option. The acquisition option agreement will expire in July of 2027, with an estimated acquisition of up to $585M and potential undisclosed earn-out payments post-acquisition. Medtronic has held a minority investment in CathWorks since 2018. The co-promotion agreement is expected to be neutral to Medtronic's fiscal year 2023 GAAP and adjusted earnings per share and neutral to accretive thereafter.

ShowHide Related Items >><<
MDT Medtronic
$88.94 /

-0.54 (-0.60%)

MDT Medtronic
$88.94 /

-0.54 (-0.60%)

07/06/22 Wolfe Research
Wolfe starts 'potential value trap' Medtronic at Underperform
07/06/22 Wolfe Research
Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform
07/05/22 Wolfe Research
Medtronic initiated with an Underperform at Wolfe Research
06/01/22 Atlantic Equities
Medtronic downgraded to Neutral from Overweight at Atlantic Equities
MDT Medtronic
$88.94 /

-0.54 (-0.60%)

MDT Medtronic
$88.94 /

-0.54 (-0.60%)

MDT Medtronic
$88.94 /

-0.54 (-0.60%)

MDT Medtronic
$88.94 /

-0.54 (-0.60%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.